Treating chronic lung Aspergillus with inhaled and oral antifungals
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) with chronic pulmonary aspergillosis (CPA)
- Your diagnosis is supported by chest CT scans and lab/pathology proof of Aspergillus
- You are not known to be resistant to itraconazole (especially if your CPA is a relapse)
- You can sign consent, and you are covered by France’s Health Care Regime (Sécurité Sociale)
- If you could become pregnant: you have a negative pregnancy test and use very reliable birth control throughout the first 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares itraconazole taken by mouth alone versus itraconazole plus steroid pills in people who have a mix of two Aspergillus lung conditions. It aims to see which approach works better to control symptoms and lung changes caused by Aspergillus infection.
This study compares two inhaled treatments (amphotericin B vs. saline) to see which one works better as maintenance therapy for people with chronic pulmonary aspergillosis. It aims to find a convenient way to keep the infection under control after initial treatment.
This research study tracks how a inhaled antifungal medicine (amphotericin B in a special lipid form) deposits and distributes in the lungs of people with chronic pulmonary aspergillosis—a long-term fungal lung infection. The goal is to understand if this inhaled approach can effectively treat this condition.
This study looks at how chronic pulmonary aspergillosis (a long-term lung infection) affects your daily life, health, and overall well-being. By joining, you'll help researchers understand what it's like to live with this condition.
This study looks at Aspergillus fungus samples from people’s lungs to understand why some become resistant to a key treatment (azole medicines). If you’ve had a sample showing Aspergillus in the past few years and live in certain areas of France, you may be able to help.
This trial tests a medication called liposomal amphotericin B for people with a serious fungal infection (aspergillosis) who also have liver problems. The goal is to see if this treatment is safe and effective for them.
Hear when a new Chronic Pulmonary Aspergillosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.